The Increasing Role of Biosimilars in Oncology

http://academiccme.com/wp-content/uploads/2018/06/Biosimilars-wpcf_400x400.jpg

Course Information

Therapautic Area: Oncology
Format(s): Webcast
Credit(s): 1.0 AMA PRA Category 1 Credit™; 1.0 CNE contact hour
Activity Dates: June 15, 2018 - June 14, 2019

 

Program Overview

This continuing education activity will focus on recent clinical trial data as well as therapeutic advances in the increasing role of biosimilars in oncology. The three expert faculty will review the fundamentals of biosimilars in oncology, including bioequivalence, totality of evidence, and interchangeability. A review of current clinical trial data of biosimilars for the treatment of various oncologic therapeutic areas will be presented. The faculty will discuss how to utilize the health care team and shared decision making to achieve improved outcomes in patients with various cancers. Upon completion of this activity, learners will gain knowledge on how to implement biosimilars in their treatment strategies to treat oncology patients.

Target Audience

Oncologists, primary care physicians, internists and advanced practice providers, including NPs and PAs, responsible for the diagnosis, treatment or management of patients with various cancers.

Learning Objectives

1. Understand the fundamentals of biosimilars in oncology, including bioequivalence, totality of evidence, and interchangeability.

2. Evaluate the current clinical trial data of biosimilars for the treatment of various oncologic therapeutic areas.

4. Utilize the health care team and shared decision making to achieve improved outcomes in patients with various cancers.

Faculty

Screen Shot 2018-06-12 at 12.29.29 PMSanjiv S. Agarwala, MD
Chief of Medical Oncology and Hematology
St Luke’s University Hospital and Health Network
Professor of Medicine
Temple University School of Medicine
Philadelphia, PA

 

Screen Shot 2018-06-12 at 12.33.46 PMAmy Goodrich, RN, BSN, MSN, CRNP-
Research Associate
The Johns Hopkins School of Medicine
Nurse Practitioner
The Sidney Kimmel Cancer Center at Johns Hopkins
Baltimore, MD

 

Screen Shot 2018-06-12 at 12.34.50 PMWasif M. Saif, MD, MBBS
Professor of Medicine
Director, GI Oncology Program
Program Leader, Experimental Therapeutics
Tufts Medical Center
Boston, MA

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

Faculty Relationship Identified With:
Sanjiv S. Agarwala, MD Nothing to disclose.
Amy Goodrich, RN, BSN, MSN, CRNP-AC Consultant/Advisor: GileadSpeaker’s Bureau: Gilead
Wasif M. Saif, MD, MBBS Grant/Research Support: TAIHO ONCOLOGY, INC.Speaker’s Bureau: TAIHO ONCOLOGY, INC.

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Boring; Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour.

Financial Support

This activity has been supported by educational grants from Amgen Inc. and Boehringer Ingelheim.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Amgen Inc. and Boehringer Ingelheim do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions.
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
8. 60 minutes of participation = 1 CNE contact hour

CE Inquiries/Special Needs

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com.

BUTTON


Provided by: AcademicCME-web